摘要
目的分析研究膝关节置换围手术期不同血液管理方法的临床疗效。方法选取本院2015年6月—2017年6月收治的69例行择期单侧膝关节置换术治疗的患者进行研究,按照随机数字表法分为观察组(n=35)和对照组(n=34)。观察组患者行膝关节置换期间用铁剂加促红素,对照组患者行膝关节置换期间进行常规血液管理。对比两组患者手术后的血红蛋白、红细胞比容和引流量。结果两组患者术前血红蛋白和红细胞比容相比差异无统计学意义(P>0.05);手术后即刻和术后6 h两组患者血红蛋白和红细胞比容组间差异有统计学意义(P<0.05);观察组患者异体输血量显著低于对照组,组间相比差异有统计学意义(P<0.05)。结论行膝关节置换术治疗的患者在围术期加用铁剂加促红素进行血液管理可以有效的减少异体输血量,改善血红蛋白和红细胞比容水平,效果显著。
Objective Analysis of the clinical effects of different blood management methods in the perioperative period of knee arthroplasty.Methods 69 patients who received elective unilateral knee arthroplasty in the hospital from June 2015 to June 2017 were selected and divided into the observation group(n=35)and the control group(n=34)according to random number table.The patients in the observation group were underwent knee replacement during iron plus erythropoietin,the control group was underwent routine blood management during total knee arthroplasty.The hemoglobin,erythrocyte specific volume and flow rate of the two groups were compared.Results Two groups of patients with preoperative hemoglobin and hematocrit showed no statistically significant difference(P>0.05);the difference of immediately after surgery and postoperative 6 h in two groups of patients with hemoglobin and hematocrit between the groups was statistically significant(P<0.05);blood transfusion volume of patients in the observation group was significantly lower than the control group,the difference was statistically significant(P<0.05).Conclusion Knee joint replacement in the treatment of patients in the perioperative use of erythropoietin and iron blood management can effectively reduce allogeneic blood transfusion,improve the hemoglobin and hematocrit level,the effect is significant.
作者
叶小东
魏俊杰
李孛
朱祖巍
YE Xiaodong;WEI Junjie;LI Bei;ZHU Zuwei(Second Department of Orthopedics,Ningde Hospital Affiliated to Fujian Medical University,Ningde Fujian 352100,China)
出处
《中国卫生标准管理》
2020年第3期63-65,共3页
China Health Standard Management
关键词
膝关节置换术
围术期
血液管理
铁剂
促红素
异体输血
knee replacement
perioperative period
blood management
iron
erythropoietin
allogeneic blood transfusion
